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Myosin VI (myo6) is the only actin-based molecular motor that
translocates along actin filaments toward the minus end. Myo6
participates in two steps of endocytic trafficking; it is recruited to
both clathrin-coated pits and to ensuing uncoated endocytic ves-
icles (UCV). Although there is evidence suggesting that the PDZ
adaptor protein GIPCsynectin is involved in the association of
myo6 with UCV, the recruitment mechanism is unknown. We show
that GIPCsynectin is required for both internalization of cell
surface receptors and for coupling of myo6 to UCV. This coupling
occurs via a mechanism wherein engagement of the GIPCsynectin
PDZ domain by C termini of internalized receptors facilitates in
trans myo6 binding to the GIPCsynectin C terminus located out-
side of the PDZ domain. Analysis of megalin, a prototypical GIPC
synectin-binding receptor, revealed that deletion of its PDZ-bind-
ing motif drastically reduced GIPCsynectin and myo6 recruitment
to UCV. Furthermore, interaction with GIPCsynectin was required
for megalin’s function, as megalin was mistargeted in the renal
proximal tubules of GIPCsynectin-null mice and these mice exhib-
ited proteinuria, a condition consistent with defective megalin
trafficking.
traffic  molecular motor  kidney
Unconventional myosins are actin-based molecular motorsimplicated in vesicle and organelle movement (1–3). Myo-
sins are comprised of two major domains: the highly conserved
motor domain that binds F-actin and converts energy from ATP
hydrolysis into directional motion along the actin filament, and
the divergent tail domain that mediates cargo binding and can
contain a variety of protein–protein and protein–lipid interac-
tionmotifs. Although associations between themyosins and their
cargoes are tail-specific, the mechanisms that govern the recruit-
ment of myosins to their cargoes have not yet been fully
determined.
Myosin VI (myo6) is involved in endocytic transport (4, 5) and
is the only actin-based molecular motor that translocates along
actin filaments toward the minus end (6). In the cell, actin
filaments are predominantly oriented with minus ends pointed
inward, supporting a role for myo6 in endocytic trafficking.
Indeed, the emerging picture is that myo6 participates in two
steps of trafficking as it is recruited to both clathrin-coated pits
(CCP) and the ensuing uncoated endocytic vesicles (UCV)
(7–9).
Myo6 associates with CCP via the adapter protein Dab2 (5).
Dab2 binds directly to clathrin, to the clathrin adaptor protein
AP-2 (10) and to myo6 (11, 12). The protein likely involved in
UCV recruitment, however, is GIPC (GAIP interacting protein,
C terminus) (13), a single Postsynaptic density 95, Disks large,
Zona occludens-1 (PDZ) domain adaptor protein also denoted
as synectin (14). Synectin’s central PDZ domain binds type I
PDZ-binding motifs (PBMs) conforming to the consensus se-
quence (ST)-X-(VA) (15). Synectin is one of themost versatile
PDZ proteins known to date, with 25 binding partners, most of
which are transmembrane receptors or adhesion molecules (e.g.,
refs. 14, 16, and 17).
Synectin captured the tail domain of myo6 in a yeast two-
hybrid screen (18). Synectin interacts with myo6 in vivo as the
two proteins collocate on UCV and can be coimmunoprecipi-
tated from membrane fractions (7). A portion of the myo6 tail
domain is sufficient to associate with UCV (7, 9). Myo6 is mainly
found in a cytoplasmic pool, where it is not complexed with
synectin or Dab2 (7), suggesting that its docking to cargo is
regulated. However, the docking mechanism remains unknown.
We found that myo6 recruitment to UCV is synectin-
dependent. PBM binding to the PDZ domain of synectin facil-
itatedmyo6 binding to a site in the C terminus of synectin located
outside of the PDZ domain. We determined that deletion of the
PBM of megalin, a known synectin-binding receptor (19), im-
paired synectin and myo6 recruitment to UCV. Finally, we found
that synectin-null mice develop proteinuria, a condition consis-
tent with defective megalin trafficking.
Results
Synectin Precedes myo6 on UCV. We considered two scenarios for
myo6 recruitment to UCV: (i) synectin is required for myo6
recruitment to UCV, serving as an essential bridge to the UCV;
(ii) synectin performs only an auxiliary role and is not required
for myo6 recruitment. To test these alternatives, we took ad-
vantage of the Snell’s waltzer (sv) mouse (20), which does not
express myo6. In both wild type (WT) and sv kidney epithelial
cells, synectin was evident on punctae that had all of the
established identifiers of UCV (7): they did not collocate with
markers for clathrin-coated vesicles (e.g., the clathrin-adaptor
AP-2; data not shown), or with early endosome markers (e.g.,
EEA1; data not shown) but could be internally labeled with
endocytosed rhodamine-conjugated EGF (R-EGF) after 2–4
min of endocytosis (Fig. 1A and B). Moreover, at this time point,
R-EGF was no longer present in CCP (data not shown), con-
firming that the R-EGFsynectin-labeled punctae were UCV.
Peak R-EGFsynectin collocation occurred after 2 min at which
39.6  5.5% and 42  2% of the synectin-associated vesicles in
WT and sv kidney cells, respectively, contained R-EGF. We
concluded that myo6 was not required for synectin recruitment
to the UCV surface.
The Presence of Both the N Terminus and the PDZ Domain of Synectin
Is Required for Synectin Targeting to UCV. To identify the minimal
region required for synectin targeting to UCV, we expressed a
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series of visual f luorescent protein (VFP, a generic term for
GFP, CFP, and YFP)-tagged domain-deletion constructs of
synectin in ARPE-19 cells, a human retinal epithelial cell line
(Fig. 2A and Table 1). In ARPE-19 cells, UCV can also be
labeled internally with rhodamine-conjugated transferrin (R-
Tfn) 2 min after the initiation of endocytosis; at that time point,
R-Tfn had exited CCP as it no longer collocated with the CCP
markers AP-2 or clathrin (7) but had not yet reached the
EEA1-positive early endosome (7, 9). Full-length VFP-synectin
targeted specifically to UCV in ARPE-19 cells, where it collo-
cated with R-Tfn after 2 min of pulse–chase uptake (Fig. 6A,
which is published as supporting information on the PNAS web
site) and with myo6 (Fig. 2B and Table 1) but did not collocate
with AP-2 or EEA1 (Fig. 6 B and C).
Interestingly, the PDZ domain alone (VFP-syn-P) was not
sufficient for UCV-association and its expression had no effect
on myo6 targeting to UCV (Fig. 2C). Furthermore, VFP-syn-P
did not collocate with endocytosed Tfn (data not shown).
Instead, the PDZ domain was recruited to focal adhesions,
overlapping with vinculin (Fig. 2D).
The smallest fragment of synectin capable of targeting to R-Tfn-
containing UCV consisted of the N and PDZ domains (VFP-syn-
NP; Fig. 2E). The UCV-targeting of this construct was as efficient
as that of VFP-fused synectin; the extent of collocation of the two
VFP-fused constructs with R-Tfn-containing vesicles after 2 min of
pulse–chase uptake was virtually identical: 68.6 7.57% and 68
7.2%, respectively (Table 1). However, VFP-syn-N expressing the
N terminus alone was diffusely distributed in the cytoplasm (Table
Fig. 1. Myo6 is not required for targeting of synectin to UCV. (A) Location of
immunolabeled synectin (green) in WT and sv mouse kidney epithelial cells
after 4 min uptake of R-EGF (red). Enlargements of boxed areas are shown in
the bottom panels of each cell type. Collocated vesicles are indicated by
arrows. (Scale bars: 10 m; enlargements, 2.5 m.) (B) Quantification of
collocation in WT kidney epithelial cells (black bars) or sv cells (white bars) of
R-EGF-containing vesicles and synectin-associated vesicles in a wide swath
along the cell periphery. R-EGF was endocytosed by pulse–chase; cells were
fixed at 0, 2, and 4 min of uptake. Synectin was detected by immunofluores-
cence. A total of 150 vesicles were counted from three different cells.
Fig. 2. The N-terminal and PDZ domains of synectin are required for UCV
binding. (A) Schematic of GFP-, YFP-, and CFP-fused synectin constructs.
Residue numbers at the ends of the N-terminal (N), PDZ (P), and C-terminal (C)
domains are shown above the YFP-synectin construct. (B–F) ARPE-19 cells
expressing VFP-fused synectin constructs (green). Boxed areas at Left are
enlarged at Right. Furthermost Right is an overlay of the two magnified fields
to its left. Vesicles showing collocation are indicated by arrows. (B) VFP-
synectin-expressing cells stained for myo6 (rabbit-anti myo6, red) revealed
significant collocation. (C) The PDZ domain (VFP-syn-P, green) was not re-
cruited to UCV, and its expression did not interfere with myo6 targeting to
vesicles in ARPE-19 cells (anti-myo6, red). (D) VFP-syn-P collocated with focal
adhesion marker vinculin (red). (E) VFP-syn-NP targeted to peripheral vesicles
internally labeled with R-Tfn (red) after 2-min pulse–chase uptake. (F) Expres-
sion of VFP-syn-NP (green) prevented myo6 (red) recruitment to UCV. (Scale
bars: 10 m; enlarged images, 2.5 m.)
Table 1. Expression pattern of synectin constructs expressed in
ARPE-19 cells and their overlap with R-Tfn and endogenous
myo6 after 2-min pulse–chase uptake
Synectin
construct
Expression
pattern
Overlap with
R-Tfn, %
Overlap with
myo6, %
VFP-syn UCV 68  7.2 70  2
VFP-syn-PDZ Diffuse NA NA
VFP-syn-N Diffuse NA NA
VFP-syn-NP UCV 68.6  7.57 20.5  8
VFP-syn-P FA None 3.00
VFP-syn-PC FA None NA
VFP-syn-C Diffuse NA NA
NA, not applicable; FA, focal adhesion.
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1). Thus, both the N terminus and the PDZ binding domains, but
not the C-terminal domain, are required and sufficient for synectin
targeting to UCV (Table 1). Because the N-terminal domain
self-associates (14, 21), dimerization appears to be required for
synectin binding to UCV.
The myo6-Binding Site Is Located in the C Terminus of Synectin.
Although VFP-syn-NP was capable of vesicle association, it
apparently lacked the myo6-binding site as upon expression in
ARPE-19 cells, myo6 was no longer recruited to UCV (Fig. 2F).
Only 20.5  8% of VFP-syn-NP punctae collocated with myo6,
versus 70  2% of VFP-synectin punctae (Table 1). Moreover,
whereas R-Tfn endocytosis was normal (Fig. 2F), R-Tfn reached
early endosomes only in 24.5  6.2% of VFP-syn-NP-expressing
cells after 15 min of uptake versus 90% of untransfected cells
and cells expressing all other VFP-synectin constructs (Fig. 7 A
and B, which is published as supporting information on the
PNAS web site). This phenotype suggests a block in the inward
transport of UCV and is similar to that seen upon expression of
myo6 motor domain mutants (7). We concluded that the myo6-
binding site is located in the C-terminal domain of synectin, and
that VFP-syn-NP expression blocked trafficking by displacing
endogenous synectin from UCV, thus preventing myo6 docking.
Coimmunoprecipitation experiments with a series of trun-
cated synectin constructs narrowed down the location of the
essential part of the myo6 binding motif to the last 29 residues
in the C terminus (Fig. 3A). A construct lacking these residues
no longer collocated with myo6 (data not shown).
A Functional PDZ Domain Is Required for Synectin Targeting to UCV.
Uncoated endocytic vesicles carry numerous types of cell surface
receptors from CCP to early endosomes. As a large number of
transmembrane receptors bind to the PDZ domain of synectin,
we hypothesized that this domain is required for synectin asso-
ciation with UCV. We replaced two consecutive residues in the
carboxylate binding loop of synectin’s PDZ domain (L142A
G143E), a mutation previously shown to impair the binding
between synectin and Gi-interacting protein (17). When ex-
pressed in ARPE-19 cells, the mutant synectin (VFP-syn-PDZ)
did not affect trafficking (Fig. 7B) and no longer targeted to
UCV (Fig. 3B) confirming that UCV association requires bind-
ing of the PDZ domain of synectin to PBMs on the UCV surface.
Ligand Binding to the PDZ Domain of Synectin Facilitates myo6
Binding to the Synectin C Terminus. Surprisingly, although the
VFP-syn-PDZ construct possessed an intact myo6-binding site
far removed from the two point mutations in the PDZ domain,
it did not coimmunoprecipitate with myo6 (Fig. 3A, lane 8). We
hypothesized that binding of the PDZ domain of synectin to its
ligand on the UCV surface is required for myo6 binding to
synectin and recruitment to UCV.
To determine the effect of ligand-binding to the PDZ domain
on the interaction between synectin and myo6, we estimated the
binding coefficients of the tail domain of myo6 to synectin in the
presence of a peptide corresponding to the cytoplasmic tail of
syndecan-4 (S4), previously shown to bind synectin (14). As a
control, we used a syndecan-4 peptide lacking the C-terminal
alanine (S4), which does not bind synectin (22). Immobilized
GST-fused myo6 tail domain (GST-M6tail) was used to pull
down endogenous synectin from ARPE-19 cell lysates in the
presence of each peptide (Fig. 8A, which is published as sup-
porting information on the PNAS web site). We constructed
saturation-binding curves to estimate the binding coefficients
between myo6 and synectin under these conditions, by varying
the fraction of ARPE-19 cell lysate in the constant total volume
used in each pull-down experiment. The calculated dissociation
constants in the presence of S4 or S4were similar to each other:
1.2 and 1.7 nM, respectively (Fig. 8B). However, the Bmax of the
binding was more than twice larger in the presence of S4 than in
the presence S4 (0.82 versus 0.35 nMs1, respectively). These
results suggest that ligand binding to the PDZ domain stabilizes
synectin in a conformation favorable for myo6 binding. To
further test the dependence of myo6 binding to synectin on
engagement of the latter’s PDZ domain, we repeated the
pull-down on lysate of ARPE-19 cells expressing VFP-syn-
PDZ. Although endogenous synectin was precipitated, GST-
M6tail failed to bind and pull down VFP-syn-PDZ (Fig. 8C).
Synectin-Null Mice Exhibit Proteinuria and Perturbed Megalin Target-
ing. The scavenger receptor megalin binds synectin (19) and
collocates with it on the lumen of kidney proximal tubules (23)
where myo6 is also located (24). Given the documented defects
in the renal function of megalin-null mice (25), we sought to
determine whether binding of megalin to synectin is essential for
megalin’s function in renal physiology. One of the renal defects
found in megalin-null mice is low molecular weight proteinuria
caused by tubular resorption deficiency (26). Urine analysis of
synectin-null mice by SDSPAGE revealed the presence of
proteins which resolved into a band pattern similar to that
of megalin-null mice. For example, urine from synectin-null mice
contained retinol-binding protein (Fig. 4A), a known megalin
ligand (27). However, the level of megalin found in the kidneys
of synectin-null mice was equivalent to that seen in WT mice
(Fig. 4B). The increased protein presence in the urine of
synectin-null mice despite the normal expression of megalin in
the proximal tubules of their kidneys suggested that megalin
recycling is defective in these mice, and that synectin is required
for proper megalin trafficking in vivo. Interestingly, myo6 ex-
pression level was 6-fold higher in synectin-null than in WT
kidneys (Fig. 4B), reflecting a compensatory response to the
impaired trafficking of megalin in the proximal tubules of
synectin-null mice.
In WT mice (Fig. 4C) megalin was primarily detected in the
endocytic region at the base of the proximal tubule cell mi-
Fig. 3. Myo6 binding to the C terminus of synectin requires a functional
synectin PDZ domain. (A) Myo6 immunoblot of ARPE-19 cell lysates trans-
fected with the indicated synectin constructs and immunoprecipitated with
anti-VFP (which recognizes all three GFP variants). Lysate lane was loaded with
10% of the immunoprecipitated sample volumes. Myo6 was coimmunopre-
cipitated only by synectin constructs that contained the full-length C-terminal
domain. Coimmunoprecipitation was abolished by the deletion of the last 29
C-terminal residues [CFP-syn (1–304)] or by inactivation of the PDZ domain by
two point mutations (X on the scheme of the YFP-syn-PDZ construct in Fig.
2A). Numbers denote molecular mass in kilodaltons. (B) L142AG143E (VFP-
syn-PDZ) expression in ARPE-19 cells counterstained with anti-myo6. The PDZ
domain mutations eliminated UCV recruitment, but had no effect on the
targeting of endogenous myo6 to UCV. (Scale bars: 10 m; Inset, 5 m.)
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crovilli, as also noted in other studies (23). In synectin-null mice,
however, megalin extended along the length of the microvilli
(Fig. 4C). A low level of megalin is normally present in microvilli
(28). Therefore, the elevated presence of megalin in the mi-
crovilli of synectin-null mice most likely reflects impairment in
megalin recycling caused by the loss of its interaction with myo6,
rather than a complete alteration of its targeting. Neither myo6
targeting nor CCP location (Fig. 4D) appeared to be perturbed
by the absence of synectin.
Megalin Recruits Synectin to UCV via PDZ Domain Interaction. Be-
cause VFP-syn-PDZ was unable to associate with UCV, we
tested whether a complementary approach, removal of the PBM
of a synectin-binding cell surface receptor, impairs receptor
trafficking by preventing synectin docking and myo6 recruit-
ment. We used a chimeric ‘‘minireceptor’’ (GFP-MegTmT)
where GFP is fused to the transmembrane and cytoplasmic
domains of human megalin (29) and a truncated version (GFP-
MegTMTPDZ) lacking the four-residue (DSEV) PBM, which
does not bind synectin (Fig. 9A, which is published as supporting
information on the PNAS web site). If synectin binding to the
PBM is required for targeting to UCV, GFP-MegTmTPDZ
should inhibit both synectin and myo6 recruitment to UCV.
We first sought to find whether the GFP-MegTmT minire-
ceptor is present on the cell surface and undergoes recycling in
ARPE-19 cells, similar to MDCK cells (29). Subcellular frac-
tionation (Fig. 9B) and surface biotinylation (Fig. 9C) confirmed
that both GFP-MegTmT and GFP-MegTmTPDZ reached the
plasma membrane in ARPE-19 cells. Both were effectively
endocytosed (Fig. 5A) and collocated to an equivalent level with
the CCP marker AP-2 (data not shown) and with endocytosed
R-Tfn (Fig. 5B). In addition, GFP-MegTmT was present in
UCV, as both endogenous synectin and myo6 overlapped with
GFP-MegTmT-labeled vesicles (Fig. 5 A and B). Expression of
GFP-MegTmTPDZ reduced the ability of endogenous synectin
and myo6 to associate with UCV to 50% of that in cells
expressing GFP-MegTmT (Fig. 5 A and B). The residual asso-
ciation of synectin with UCV in GFP-MegTmTPDZ-
expressing cells suggests that the population of cell surface
receptors present in UCV is heterogeneous, frequently contain-
ing more than a single synectin-binding species.
Discussion
We conclude that myo6 binding to synectin depends on the
engagement of synectin’s PDZ domain: (i) although myo6 bound
synectin, it did not coimmunoprecipitate with VFP-syn-PDZ, a
Fig. 4. Proteinuria and altered megalin distribution in synectin-null mice. (A)
Coomassie-stained gel of urine samples from WT and from synectin-null mice
revealed the presence of multiple bands in the synectin-null sample that were
absent in the WT sample, indicative of proteinuria. Immunoblotting of similar
urine samples detected the presence of the megalin ligand retinol-binding
protein in the synectin-null urine sample. (B) Immunoblots of synectin, myo6,
and megalin in WT and synectin-null mice. Fifty micrograms of total protein
was loaded in each lane. The synectin-null myo6 band was 6-fold heavier
than the WT one, as measured by densitometry. The -tubulin immunoblot
was used as a loading control. (C andD) Confocal images of 4-m cryosections
of WT and synectin-null mouse kidneys stained for megalin (green, Left)
and F-actin (blue, Center) (C) or for AP-2 and F-actin (D). (Scale bars: 5 m;
Inset, 2.5 m.)
Fig. 5. Synectin binding to the PBM of megalin is required for synectin and
myo6 recruitment to UCV. (A) Indirect immunofluorescence staining of
ARPE-19 cells expressing GFP-MegTmT or GFP-MegTmTPDZ stained for myo6
or synectin. The second and fourth rows are enlargements of the boxed
regions in the first and third rows. Filled arrows indicate collocation of GFP
constructs, CFP constructs, and R-Tfn; open arrows indicate absence of collo-
cation. (Scale bars: 10 m; enlarged images, 2.5 m.) (B) Quantification of the
collocation of GFP-MegTmT-containing (black bars) or GFP-MegTmTPDZ-
containing (white bars) vesicles with endogenous synectin (syn), myo6 (myo6),
AP-2, and R-Tfn along the cell periphery. A total of 150 vesicles were counted
from at least three cells.
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synectin construct that has a nonfunctional PDZ domain but still
contains a potential myo6-binding site; (ii) expression of VFP-
syn-PDZ did not block myo6 recruitment to UCV, as would be
predicted if myo6 binding to the C terminus of synectin occurred
in the absence of PDZ-domain engagement; (iii) the binding of
the myo6 tail domain to synectin in vitro was enhanced in the
presence of a synectin PDZ ligand.
Myo6 recruitment appears to require interaction between the
PBMs of engulfed receptors and synectin’s PDZ domain be-
cause: (i) engagement of synectin’s PDZ domain facilitated its
binding to myo6 in vitro; (ii) the PBM of megalin was required
for synectin and myo6 recruitment to megalin-containing UCV;
(iii) megalin targeting to the apical endocytic region of proximal
tubule epithelial cells, presumably a myo6-dependent process,
was disrupted in kidneys of synectin-null mice, thus impairing
megalin’s function.
The PDZ domain may regulate myo6 binding to the C-terminal
domain of synectin in two possible ways: (i) synectin may predom-
inantly reside in a conformation where the PDZ domain interacts
with the C terminus, physically blocking access to themyo6-binding
site; (ii) alternatively, ligand binding to the PDZ domain may be
transmitted to the C terminus by an allosteric mechanism. In either
scenario, engagement of the PDZ domain would stabilize synectin
in a conformationwhere themyo6 binding site is exposed. Thus, the
PDZ domain of synectin functions as an active regulatory compo-
nent conditioning myo6 binding to synectin upon synectin’s asso-
ciation with UCV.
PDZ domains are thought to function primarily as passive
binding modules (30). The only known instance of a ligand-
dependent intramolecular regulation by a PDZ domain is the
activation of protease activity of the bacterial protein DegS (31).
Conceivably, cooperative binding mechanisms similar to the
ones occurring in DegS and synectin may be more prevalent than
currently appreciated.
Evidence from yeast two-hybrid assays suggests that synectin
dimerization involves its N terminus (14, 21). In support, we
detected by size exclusion chromatography that synectin is
present as a dimer in solution under physiological conditions
(data not shown). The functional significance of synectin dimer-
ization is intriguing because a recent study suggested that myo6
exists primarily as a monomer but can dimerize when in very
close proximity to another myo6 molecule (32). Myo6 dimer-
ization was inhibited by the myo6 cargo binding domain in vitro,
indicating that a cargo binding-dependent mechanism is re-
quired for proximity-based dimerization. It is likely that synectin
dimerization, which brings two myo6 molecules in close prox-
imity, promotes recruitment and subsequent dimerization of
myo6.
Myosins I, V, VI, VII, and X participate in intracellular
organelle trafficking (33), but only the cargo docking mechanism
of myosin Va is well characterized (34, 35). Myosin V targeting
is mediated by organelle-specific Rab GTPases, some of which
bind to myosin Va directly, and some via adaptor proteins.
However, this recruitment mechanism is very different from that
of myo6 (Fig. 10A, which is published as supporting information
on the PNAS web site).
Myo6 can be recruited to two distinct cargoes, UCV and CCP,
although it is recruited to UCV in most cell types (8, 9). Two
mechanisms modulate the ability of myo6 to target to CCP, the
alternative splicing of the myo6 tail domain and the expression
level of Dab2, an adapter protein that binds to clathrin, clathrin
adapters, and myo6 (9). Only under conditions where Dab2
levels are high is myo6 targeting to CCP observed. Dab2 can also
bind megalin (36) and as such may link megalin to myo6 in CCP.
Unlike synectin, Dab2 binds to the internalization FXNPXY
motif in megalin’s cytoplasmic domain (36). Notably, renal
proximal tubule epithelial cells from Dab2-null mice are defec-
tive in protein uptake (37), but this is due to decreased synthesis
or increased turnover of megalin (38). In contrast, megalin levels
remain unchanged in synectin-null mice (Fig. 4B).
Based on these differences, we suggest that Dab2 and synectin
perform nonoverlapping functions with regards to megalin’s
endocytosis and transport. Dab2 likely plays a role early in
endocytosis, perhaps to cluster the receptor in CCP or to signal
receptor endocytosis. Synectin may act at two stages: (i) After
the completion of endocytosis and vesicle uncoating (Fig. 10A),
which may explain why myo6 location appeared essentially
unchanged in synectin-null mice, as Dab2 could still recruit myo6
to CCP. The lack of myo6 association with UCV would be hard
to discern in the dense apical endocytic region of the proximal
tubule epithelial cells. (ii) Synectin could be required for megalin
translocation down microvilli toward CCP located near the
microvillus base (Fig. 10B). Actin filaments are oriented with
their minus ends at the microvillus base, facilitating the retro-
grade translocation of myo6 and its cargo toward the base.
Indeed, myo6 was reported to serve a similar function in the
microvillar transport of the sodium proton exchanger NHE3
during acute renal hypertension (39). Loss of myo6-driven
translocation may explain the redistribution of megalin seen in
synectin-null mice, causing accumulation of the protein in mi-
crovilli rather than at the base of these structures.
The large and diverse group of proteins that bind to synectin’s
PDZ domain does not seem to have a common functional theme.
The only known binding partner of synectin that does not
interact with the PDZ domain is myo6. It is conceivable that this
interaction underlies synectin’s function, namely that synectin
serves as a ‘‘universal’’ adapter of myo6 to a myriad of cargoes.
Materials and Methods
Expression Constructs. Expression constructs are described in
detail in Supporting Text, which is published as supporting
information on the PNAS web site.
Antibodies. Antibodies are listed in Supporting Text. All pur-
chased antibodies were used at concentrations recommended by
the manufacturer.
Isolation of Mouse Kidney Epithelial Cells. Kidney epithelial cells
from Snell’s waltzer mice were isolated by collagenase digestion
as described in the Supporting Text. For immunofluorescence,
cells were grown on glass coverslips coated with 50 gml
collagen IV (BD Biosciences, Franklin Lakes, NJ).
Fixation of Mouse Kidneys. WT and synectin-null mice (40) anes-
thetized by Avertin were perfused through the left ventricle with
PBS and by 4% paraformaldehyde (PFA)PBS. Kidney blocks of
2 2mmwere fixed in PBS20mMEGTA4%PFA for 5min,
rinsed in PBS20 mM EGTA, quenched in 0.05% NaBH4PBS
EGTA for 10 min, infiltrated with 1 M sucrosePBSEGTA for
2 h on ice, embedded in OCT (Tissue-Tek), and frozen in liquid
nitrogen.
Analysis of Urine Samples.Urine pooled from three WT and three
synectin-null mice was separated on 12% acrylamide gels and
stained by Coomassie blue or immunoblotted for retinol-binding
protein.
Uptake of R-Tfn or R-EGF. Pulse–chase and steady-state R-Tfn or
R-EGF (1 gml; Invitrogen, Carlsbad, CA) uptake assays were
performed as described (7). Collocation of R-EGF-containing
vesicles with endogenous synectin or AP-2 was quantified by
counting vesicles where the corresponding fluorescence emis-
sions overlapped. At least 50 vesicles from three different cells
were quantified for each time point.
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Immunofluorescence Microscopy. Cells grown on coverslips or
4-m kidney cryosections were processed and imaged as de-
scribed (7). Collocation of vesicles associated with VFP-synectin
constructs and endogenous myo6 or R-Tfn was quantified as
above.
GST Pull-Down Assays. GST-M6tail and polyhistidine-tagged syn-
ectin fragment (syn-120–333) were prepared as described (9, 41).
ARPE-19 cells, lysed as described (7), were rotated for 1 h at 4°C
in the presence of either 50 M peptide corresponding to the C
terminus of syndecan-4 (S4; RMKKKDEGSYDLGKKPIYKK-
APTNEFYA; Genemed Synthesis, South San Francisco, CA) or
S4 lacking the C-terminal alanine (S4), thus saturating the
endogenous synectin in ARPE-19 cells whose concentration was
estimated by densitometric calibration (Fig. 11, which is pub-
lished as supporting information on the PNAS web site) as150
nM. Lysates were rotated with 40 l of GST-M6tail coupled to
glutathione-Sepharose beads (Amersham Pharmacia Bio-
sciences, Piscataway, NJ) for 1 h at 4°C. Proteins were eluted
from beads in boiling SDSPAGE sample buffer and immuno-
blotted by synectin or VFP antibodies. TotalLab (Nonlinear) and
Prism (GraphPad) were used for band densitometry and non-
linear regression, respectively.
Subcellular Fractionation. ARPE-19 cells grown in six-well dishes
were transfected with 3 g per well of pEGFP, pGFP-
MegTmT, or pGFP-MegTmTPDZ and lysed 36 h after
transfection in PBS5 mM EDTA1% Triton X-100. Pellets
obtained from total cell lysate were lysed as described (7).
Nuclei were removed by centrifugation for 5 min at 1,000  g.
Pellets produced by further centrifugation at 14,000  g for 20
min comprised the plasma membrane fraction. Samples sep-
arated on 4–20% gradient SDS polyacrylamide gels were
immunoblotted as described (7).
Biotinylation Assay. Cells were transfected in six-well dishes as
described above and surface-labeled with EZ-link Sulfo-NHS-
SS-biotin (Pierce, Rockford, IL) on ice. Surface receptors were
pulled down with streptavidin beads as described (42).
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